Trial Profile
Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2022
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary) ; Quetiapine (Primary) ; Ziprasidone (Primary)
- Indications Psychotic disorders
- Focus Therapeutic Use
- Acronyms PAFIP II; PAFIP2_3Y
- 24 Jan 2020 Results assessing effectiveness of olanzapine, risperidone, haloperidol, aripiprazole, ziprasidone and quetiapine for the treatment of first episode of psychosis at 3-years, published in the International Journal of Neuropsychopharmacology.
- 12 Sep 2018 Results published in the International Journal of Neuropsychopharmacology
- 21 Aug 2015 New trial record